## Carmelo Pozzo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9098449/publications.pdf

Version: 2024-02-01

567144 552653 1,101 33 15 26 citations h-index g-index papers 33 33 33 1614 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. European Journal of Cancer, 2006, 42, 2212-2221.	1.3	481
2	Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: AÂsystematic review and meta-analysis. Clinical Nutrition, 2020, 39, 2045-2054.	2.3	73
3	Liver Resection for Primarily Unresectable Colorectal Metastases Downsized by Chemotherapy. Journal of Gastrointestinal Surgery, 2007, 11, 318-324.	0.9	55
4	Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN, 2020, 38, 28-42.	0.5	49
5	Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use. Drugs, 2013, 73, 2003-2015.	4.9	48
6	Chance of Cure Following Liver Resection for Initially Unresectable Colorectal Metastases: Analysis of Actual 5-Year Survival. Journal of Gastrointestinal Surgery, 2013, 17, 352-359.	0.9	35
7	Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen., 1998, 82, 1460-1467.		33
8	Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. Quality of Life Research, 2009, 18, 853-861.	1.5	33
9	Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. Journal of Surgical Oncology, 2005, 89, 227-236.	0.8	32
10	Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer, 2007, 10, 104-111.	2.7	29
11	Is There an Optimal Chemotherapy Regimen for the Treatment of Advanced Gastric Cancer That Will Provide a Platform for the Introduction of New Biological Agents?. Oncologist, 2008, 13, 794-806.	1.9	28
12	Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treatment Reviews, 2008, 34, 293-301.	3.4	26
13	Coronary artery spasm induced by capecitabine. Journal of Cardiovascular Medicine, 2006, 7, 136-138.	0.6	25
14	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. Journal of Clinical Oncology, 2022, 40, 2878-2888.	0.8	24
15	The Facts about Food after Cancer Diagnosis: A Systematic Review of Prospective Cohort Studies. Nutrients, 2020, 12, 2345.	1.7	20
16	Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. Nutrients, 2020, 12, 3101.	1.7	17
17	Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study. Nutrients, 2021, 13, 960.	1.7	16
18	Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. Internal and Emergency Medicine, 2021, 16, 1341-1356.	1.0	12

#	Article	IF	CITATIONS
19	7-Year Survival Results of Perioperative Chemotherapy with Epidoxorubicin, Etoposide, and Cisplatin (EEP) in Locally Advanced Resectable Gastric Cancer: Up-to-date Analysis of a Phase-II Study. Annals of Surgical Oncology, 2008, 15, 2146-2152.	0.7	11
20	Preoperative therapy and long-term survival in gastric cancer: One size does not fit all. Surgical Oncology, 2018, 27, 575-583.	0.8	11
21	Nutritional Support in Lung Cancer Patients: The State of the Art. Clinical Lung Cancer, 2021, 22, e584-e594.	1.1	11
22	A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer. Journal of Surgical Oncology, 2020, 122, 293-305.	0.8	10
23	Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. World Journal of Gastrointestinal Surgery, 2021, 13, 885-903.	0.8	10
24	Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study). Cancers, 2021, 13, 2098.	1.7	5
25	5-Fluorouracil (FU) with folinic acid (FA) and mitomycin c (MMC) in the adjuvant treatment of colorectal carcinoma. part i. evaluation of toxicity. Medical Oncology and Tumor Pharmacotherapy, 1991, 8, 69-73.	1.0	3
26	Recurrent disease four years after surgery and adjuvant chemotherapy. Cancer Treatment Reviews, 2008, 34, S8-S11.	3.4	2
27	New biomarkers to predict response to oxaliplatin-based chemotherapy in metastatic colorectal cancer: KRAS and ERCC1 Journal of Clinical Oncology, 2012, 30, 500-500.	0.8	2
28	What Chemotherapy Is Practicable in Aged Patients?., 2018,, 331-337.		0
29	Pathologic complete response after neoadjuvant chemotherapy as a real surrogate endpoint of outcome for all breast cancer subtypes? Results of a single institution experience Journal of Clinical Oncology, 2015, 33, e11613-e11613.	0.8	0
30	ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer patient: preliminary data from liquid biopsy Journal of Clinical Oncology, 2015, 33, 11033-11033.	0.8	0
31	Emergency care in cancer patients: Data on 15,623 cases from a large volume single centre Journal of Clinical Oncology, 2015, 33, e17577-e17577.	0.8	0
32	Resection of lung metastases from colorectal cancer: Analysis of outcome and prognostic factors Journal of Clinical Oncology, 2015, 33, e14556-e14556.	0.8	0
33	Potential role of IL-8 and eNOS polimorphisms in the outcome of bevacizumab-treated colorectal cancer patients: an exploratory analysis Journal of Clinical Oncology, 2015, 33, e22015-e22015.	0.8	0